ARCHIVES

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

NCI to Implement Plan For Stepped Up Patient Accrual Despite Reservations OF Group Chairmen

December 4, 1987

Oral UFT Equivalent To FULV In Stage II and III Colon Cancer

July 30, 2004

NCAB Committee Approves Recompletion Of Support Contracts

October 7, 1988

M.D. Anderson Wins Nearly $54 Million in ARRA Funding From NIH

November 6, 2009

Vanderbilt Wins NCI Core Grant Renewal with 12.7 Percent Funding increase

December 3, 2010

Foundations Invites Antitobacco Proposals

October 15, 1993